Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Relaxin supports implantation and early pregnancy in the marmoset monkey (2009)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Einspanier, Almuth
    Lieder, Kai
    Husen, Bettina
    Ebert, Katja
    Lier, Susanne
    Einspanier, Ralf
    Unemori, Elaine
    Kemper, Martina
    Quelle
    Annals of the New York Academy of Sciences; 1160 — S. 140–6
    ISSN: 0077-8923
    Sprache
    Englisch
    Verweise
    DOI: 10.1111/j.1749-6632.2009.03947.x
    Pubmed: 19416176
    Kontakt
    Institut für Veterinär-Biochemie

    Oertzenweg 19 b
    14163 Berlin
    Tel.+49 30 838 62225 Fax.+49 30 838-62584
    email:biochemie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    To test the hypothesis that relaxin is an important factor supporting implantation, two approaches have been carried out using a human-relevant animal model, the marmoset monkey. First, uterine mRNA transcription and protein expression during the implantation phase in the conceptive and nonconceptive cycles were examined. Second, functional parameters were analyzed to assess the in vivo effects of exogenous applied relaxin throughout implantation. Relaxin and its receptor, RXFP1, were highly upregulated shortly before and during the physical process of implantation, indicating that relaxin is an important factor for remodeling and immunotolerance. The action of relaxin on the uterus was accompanied by an increase of estrogen-associated factors and macrophage infiltration, suggesting redundant systems necessary for successful implantation. The data from relaxin-treated animals supported those obtained from naive tissues in terms of increases in angiogenesis as well as earlier and faster growth of the uterus and placenta in the relaxin-treated marmoset monkey group, resulting in parturition 7-10 days earlier than the control group, but not pathological. In general, relaxin is very effective in preparing the endometrium for implantation. These findings should encourage further clinical research regarding introducing relaxin for pathological pregnancies, such as early pregnancy failure or insufficient placenta.